Foundation Medicine is your Biopharma Services partner across the global therapy development lifecycle.

Biopharma Services

We are your essential partner from initial biomarker discovery to companion diagnostic approval and commercialization of a new therapy.

Gain confidence and meet your specific program needs with our scientific and regulatory expertise and our global portfolio of NGS tests, data, and services.

Proven Leadership in Biopharma Services

Comprehensive Biomarker Testing

  • Blood- and tissue-based CDx approved tests
  • DNA, RNA, ctDNA for solid tumors and heme malignancies

Clinical and Genomics Data

  • >125k patients in our CGDB (clinical and genomics data)1


The Global Leader in Approved Companion Diagnostic Indications*

  • Nearly 60% of all approved CDx indications for NGS testing across US and Japan2
Biopharma Discovery & Research Services

Leverage our portfolio of comprehensive NGS testing and clinical and genomics data to:

  • GENERATE new insights & detect biomarkers
  • INFORM the design of upcoming trials
  • IDENTIFY patients that could benefit from your therapy
  • DETECT early treatment response and resistance

Learn more about Biomarker Discovery & Translational Research

Biopharma Enrollment & CDx Development

Our clinical trial enrollment and regulatory expertise can help you accelerate your trials and approval timelines:

  • EXPERIENCE: Over 850 clinical trials supported across Phase I/II/III1
  • ACCELERATE: Identify biomarker-positive patients for trial enrollment with FoundationReachTM
  • LEADER: Nearly 60% of all CDx indications for NGS testing in the United States and Japan2
  • GLOBAL: Support global trials, including sites in Europe under IVDR or in China through a local partner

Learn more about Clinical Development & CDx

Biopharma Commercial Launch Support

Our global commercial footprint can support your needs in test and therapy commercialization and market access:

  • MAXIMIZE your therapy impact and commercial success with our global reach
  • PARTNER to drive education and adoption of new CDx biomarkers matched to your therapy
  • TARGET and support your commercial launch efforts with de-identified alerts on biomarker populations

Learn more about Access & Commercialization

Learn more about how Foundation Medicine can partner with you to advance your therapy development

Download our Biopharma Services Overview Here

Contact our Biopharma Team

Need More Details? 

We are here to help. Contact our Biopharma Team for more information. 

Contact Us

* Data on file, Foundation Medicine, Inc., data as of Dec. 6, 2023.

1. Data on file, Foundation Medicine, Inc., 2023.

2. Data on file, Foundation Medicine, Inc., data as of May 4, 2023.

3. For Research Use Only. Not for use in diagnostic procedures.

4. Data on file, Foundation Medicine, Inc., 2022

Important Safety Information


FoundationOne CDx

FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit